Igor E. Shohin — Effective GLP-regulation as a part of drug products efficacy and safety for patients: Russian bioanalytical laboratories experience
GLP in Russia
REGULATION OF THE DISTRIBUTION OF PHARMACEUTICAL PRODUCTS IN THE RUSSIAN FEDERATION INCLUDING EAEU REGULATIONS
Arina Selezneva — Ways to improve the System of Good Laboratory Practices in the EAEU: experience and suggestions
Dr. Rubina Bose — India’s approach to GDP for vaccines: challenges and lessons learnt
Marina Mishustina — Novo Nordisk experience in technology transfers
QF. Maysie Vallejos Campos — Good Laboratory Practices in Chile: regulation and inspection issues
EXPERIENCE OF THE «GEDEON RICHTER-RUS» IN CONDUCTING TECHNOLOGY TRANSFER
Ivkin Dmitry — Bringing the Centre of Preclinical Trials to Compliance with GLP Requirements
Omega-3 is our natural healer
Advances in ARCSA regulations for the certification of Good Practices of national pharmaceutical establishments, focused on becoming a Level 4 Reference Agency
Benchmarking of Good Manufacturing Practices (GMP) in Production of Medicines and Dietary Supplements
Dr.-Ing. Stephan Roenninger — Internationally Recognized Requirements on Good Manufacturing, Storage and Distribution Practice
Ferenc Lukács PhD — National GLP program In Hungary
Ferenc Lukács PhD — Regulatory requirements of Technological transfer
Dr. Suzana Jukić — Croatian/EU regulatory requirements for the Technology transfer in pharmaceutical manufacturing
Mr. CAO Yi — China’s Requirement of Transfer of Technology in Manufacturing
Dr. Patricia Aprea — Transfer technology requirements in Argentina for pharmaceutical products
Transfer. Brief overview of regulatory requirements
Marina Mishustina — Novo Nordisk experience in technology transfers
MSc. Lisette Pérez Ojeda — Cuban regulatory experience in context of transfer technology for biological products
Meshalkin Mikhail — Takeda’s Experience of Technology Transfer
Novo Nordisk experience in technology transfers
O. Maklakova — On technology transfer and communication with PQS
D.A. Rozhdestvensky — SINGLE DATABASES SINGLE REGISTER INTRODUCTION ISSUES
Pharmaceutical market transition to Eurasian Economic Union rules
Types of inspections according to the rules of the EAEU (within the framework of registration procedures)
D.A. Rozhdestvensky — SINGLE DATABASES SINGLE REGISTER INTRODUCTION ISSUES
Circulation of medicinal products at the single market - control, putting into circulation in the territories of the Member States
Kravchuk Anna — Pharmaceutical inspections: 3rd level EEC acts
N.T. Abdyrasulova — Putting Medicines into Circulation in the EAEU
Volovich Natalia — Circulation of Medicines in the EAEU Market
Sottaeva Madina — TYPES OF INSPECTIONS ACCORDING TO THE RULES OF THE EAEU. EXTRAORDINARY INSPECTIONS
T. Yeritsan — Acute issues of integration within the framework of a unified pharmaceutical market
SUPPORT IN THE DEVELOPMENT OF NEW PHARMACEUTICAL FACTORIES IN THE BOLIVARIAN REPUBLIC OF VENEZUELA
V. Studenok, O. Kremlev, V. Gegechkori — Standard samples as a tool for metrological support of the pharmaceutical industry. State and development prospects
Solodova Raziya — Overview of the Russian pharmaceutical market. Development of full-cycle domestic production: tasks, opportunities and prospects
Pr. K.Mansouri — Current development of the pharmaceutical market
Dr. Thomas Kirchlechner — The complex nature of biological medicine & state-of-art technology of biosimilar development
Maj. Gen. Md. Mahbubur Rahman — Key Regulatory Actions of Directorate General of Drug Administration (Bangladesh) During Covid-19 Pandemic
MSc. Olga Lidia Jacobo Casanueva — CECMED regulatory actions against the pandemic: reflection and forward path
Pr. K. Mansouri — Regulatory actions during the pandemic Covid-19
Dr. Jérôme Lepeintre — EU Coordination during COVID-19 Pandemic: Success or Disaster?
Logistic Centers: The Popular Post Covid Figure
Neale Baldwin — GMP Inspections during the Pandemic – an Australian perspective
Smirnov Valery — Reference Materials in Scientific Research
A. Mikhaylova — Distinctive Features of Quality Assurance in Manufacture of Biological Drugs
Dr. Patricia Aprea — Requirements of good practices for manufacturing biological products in Argentina
Dr. Patricia Aprea — Requirements of good practices for manufacturing biological products in Argentina
